Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Israel
· Delayed Price · Currency is ILS · Price in ILA 1,286.00
-118.00 (-8.40%)
Apr 29, 2025, 5:32 PM IDT
TLV:REKA Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 321.71 | 321.66 | 292.39 | 263.95 | 265.47 | Upgrade
|
| Revenue Growth (YoY) | 0.01% | 10.01% | 10.78% | -0.57% | 35.10% | Upgrade
|
| Cost of Revenue | 249.76 | 241.46 | 213.69 | 198.79 | 196.83 | Upgrade
|
| Gross Profit | 71.95 | 80.2 | 78.71 | 65.16 | 68.64 | Upgrade
|
| Selling, General & Admin | 73.71 | 71.04 | 60.45 | 49.62 | 46.2 | Upgrade
|
| Research & Development | 4.07 | 3.78 | 3.23 | 2.08 | 1.54 | Upgrade
|
| Other Operating Expenses | 1.51 | 2.48 | 1.77 | 0.55 | 0.01 | Upgrade
|
| Operating Expenses | 79.29 | 77.3 | 65.46 | 52.25 | 47.75 | Upgrade
|
| Operating Income | -7.34 | 2.91 | 13.25 | 12.91 | 20.89 | Upgrade
|
| Interest Expense | -6.71 | -8.29 | -5.65 | -5.63 | -5.81 | Upgrade
|
| Interest & Investment Income | 0.36 | 0.71 | 0.04 | 0.07 | 0.19 | Upgrade
|
| Earnings From Equity Investments | 0.01 | -0.22 | - | -0.13 | -0.64 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.04 | -0.32 | 0.14 | -0.79 | -0.38 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.77 | -1.29 | -0.83 | 0.06 | -0.26 | Upgrade
|
| EBT Excluding Unusual Items | -14.4 | -6.5 | 6.96 | 6.48 | 13.99 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.02 | 0.02 | -0.02 | 1.19 | 0.14 | Upgrade
|
| Gain (Loss) on Sale of Assets | 23.71 | 0.05 | 0 | 0.05 | 0.03 | Upgrade
|
| Other Unusual Items | -1.36 | -0.62 | -6.59 | - | - | Upgrade
|
| Pretax Income | 7.93 | -7.05 | 0.36 | 7.71 | 14.16 | Upgrade
|
| Income Tax Expense | 1.72 | -0.14 | 2.4 | 1.1 | 3.36 | Upgrade
|
| Earnings From Continuing Operations | 6.21 | -6.91 | -2.04 | 6.61 | 10.8 | Upgrade
|
| Net Income to Company | 6.21 | -6.91 | -2.04 | 6.61 | 10.8 | Upgrade
|
| Minority Interest in Earnings | - | 0 | 0 | 0.01 | - | Upgrade
|
| Net Income | 6.21 | -6.91 | -2.04 | 6.62 | 10.8 | Upgrade
|
| Net Income to Common | 6.21 | -6.91 | -2.04 | 6.62 | 10.8 | Upgrade
|
| Net Income Growth | - | - | - | -38.65% | 170.81% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| EPS (Basic) | 0.54 | -0.61 | -0.18 | 0.58 | 0.95 | Upgrade
|
| EPS (Diluted) | 0.54 | -0.61 | -0.18 | 0.58 | 0.95 | Upgrade
|
| EPS Growth | - | - | - | -38.65% | 170.81% | Upgrade
|
| Free Cash Flow | 17.85 | 16.86 | 32.07 | 7.68 | -7.35 | Upgrade
|
| Free Cash Flow Per Share | 1.56 | 1.48 | 2.81 | 0.67 | -0.64 | Upgrade
|
| Dividend Per Share | - | - | - | 0.868 | - | Upgrade
|
| Gross Margin | 22.36% | 24.93% | 26.92% | 24.69% | 25.86% | Upgrade
|
| Operating Margin | -2.28% | 0.90% | 4.53% | 4.89% | 7.87% | Upgrade
|
| Profit Margin | 1.93% | -2.15% | -0.70% | 2.51% | 4.07% | Upgrade
|
| Free Cash Flow Margin | 5.55% | 5.24% | 10.97% | 2.91% | -2.77% | Upgrade
|
| EBITDA | 17.31 | 26.03 | 40.73 | 35.77 | 40.61 | Upgrade
|
| EBITDA Margin | 5.38% | 8.09% | 13.93% | 13.55% | 15.30% | Upgrade
|
| D&A For EBITDA | 24.65 | 23.12 | 27.48 | 22.86 | 19.71 | Upgrade
|
| EBIT | -7.34 | 2.91 | 13.25 | 12.91 | 20.89 | Upgrade
|
| EBIT Margin | -2.28% | 0.90% | 4.53% | 4.89% | 7.87% | Upgrade
|
| Effective Tax Rate | 21.72% | - | 672.27% | 14.21% | 23.73% | Upgrade
|
| Advertising Expenses | 2.51 | 3.16 | 1.3 | 1.63 | 1.36 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.